For a long time, ESR and CRP have been the primary biomarkers for assessing inflammation. However, these "acute-phase" proteins have limitations in specificity and sensitivity for identifying low-grade inflammation. Other biomarkers, such as BAFF and PAF, which are linked to specific immune pathways, are more accurate for this type of inflammation.